Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer

Published:2021-03-09 Issue:14 Volume:40 Page:2596-2609
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Ma Shiqi,Zhang Lu,Ren Yuan,Dai Wei,Chen Tingqing,Luo Liping^ORCID,Zeng Juan,Mi Kun,Lang Jinyi^ORCID,Cao Bangrong^ORCID

Funder

National Natural Science Foundation of China

Basic Research Programs of Sichuan Province

Innovation Program of Sichuan Medical Association Science for Youth (grant No. Q18009).

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/s41388-021-01734-4.pdf

Reference30 articles.

1. Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol. 2018;15:694–708.

2. Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:I10–9.

3. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25.

4. Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, de Stricker K, Grauslund M, et al. Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance. Cancers. 2019;11:57.

5. Nagano T, Tachihara M, Nishimura Y. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells. 2018;7:16.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EREG silencing inhibits tumorigenesis via inactivating ERK/p38 MAPK pathway in pancreatic ductal adenocarcinoma;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-10

2. Targeting tumor-associated macrophages to reverse antitumor drug resistance;Aging;2024-05-23

3. Role of Epiregulin in Lung Tumorigenesis and Therapeutic Resistance;Cancers;2024-02-07

4. Identification of a novel endocytosis‑associated gene signature for prognostic prediction in lung adenocarcinoma;Oncology Letters;2023-10-12

5. Potential roles of tumor microenvironment in gefitinib-resistant non-small cell lung cancer: A narrative review;Medicine;2023-10-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3